Axel-Rainer Hanauske

Author

Asklepios Klinik St. Georg

Also Known As

A R Hanauske, A- Hanauske, A. Hanauske, A.-R. Hanauske, Axel-Rainer Hanauske

Publications

622

Citations

H-Index

Concepts

All Affiliations

Asklepios Klinik St. Georg Rutgers, The State University of New Jersey Rutgers New Jersey Medical School Eli Lilly (United States)

About

Axel-Rainer Hanauske is an author at Asklepios Klinik St. Georg specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	525
2	Cell Biology	2	2	118
3	Health Sciences	1	1	85
4	Biochemistry	1	1	286
5	Immunology	1	1	30

Axel-Rainer Hanauske

Publications

560

Citations

H-Index

Page 1

	Year	Citations
The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor Kyle D. Holen, Leonard B. Saltz, Ellen Hollywood, Investigational New Drugs BiochemistryMedicineBiologic EffectsPharmacotherapyPharmacology	2007	286
In vitro chemosensitivity of freshly explanted tumor cells to pemetrexed is correlated with target gene expression Axel-Rainer Hanauske, Ulrike Eismann, Olaf Oberschmidt, Investigational New Drugs Tumor HeterogeneityMedicineTumor CellsTumor TargetingCell Biology	2007	85
Phase II study of MTX-HSA in combination with Cisplatin as first line treatment in patients with advanced or metastatic transitional cell carcinoma Claus Bolling, T. Graefe, C. Lübbing, Investigational New Drugs UrologyMedicinePhase Ii StudyPathologyImmune Checkpoint Inhibitor	2006	77
Drug-Based Lead Discovery: The Novel Ablative Antiretroviral Profile of Deferiprone in HIV-1-Infected Cells and in HIV-Infected Treatment-Naive Subjects of a Double-Blind, Placebo-Controlled, Randomized Exploratory Trial Deepti Saxena, Michael Spino, Fernando Tricta, PLoS ONE	2016	35
Antitumor activity of enzastaurin (LY317615.HCl) against human cancer cell lines and freshly explanted tumors investigated in vitro soft-agar cloning experiments Axel-Rainer Hanauske, Olaf Oberschmidt, Hartmut M. Hanauske‐Abel, Investigational New Drugs Tumor BiologyOncologyAntitumor ActivityMedicineTumor Targeting	2007	33
Clinical and pharmacokinetic study of oral NK611, a new podophyllotoxin derivative Olivia Pagani, Massimo Zucchetti, Cristiana Sessa, Cancer Chemotherapy and Pharmacology New Podophyllotoxin DerivativeOral Nk611MedicineImmunologyPharmacokinetic Study	1996	30
Results of a phase II trial of S-1 as first-line treatment of metastatic pancreatic cancer (CESAR-study group) Beate Schultheis, Dirk Strumberg, Lothar Bergmann, Investigational New Drugs Surgical OncologyPancreatic CancerPhase Ii TrialGastrointestinal OncologyMedicine	2011	14

Page 1